BMS plans to remodel its downsized Syracuse plant

Bristol-Myers Squibb plans to demolish half of the 118 buildings at its East Syracuse operation in a facelift that reflects the changes that have occurred inside the drug plant. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.